Dendritic cell-based vaccine in the treatment of patients with advanced melanoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 4, 2007, Pages 501-507

  Zhang, Sheng ^a   Wang, Qing ^b   Miao, Beiping ^c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

Dendritic cells; Immunotherapy; Melanoma; Self tolerance

Indexed keywords

CANVAXIN; DENDRITIC CELL VACCINE; PLACEBO; ANTIGEN; CANCER VACCINE;

ADVANCED CANCER; AUTOIMMUNE DISEASE; CANCER PATIENT; CELL MATURATION; CLINICAL STUDY; CLINICAL TRIAL; DENDRITIC CELL; DRUG FEVER; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOTHERAPY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CANCER STAGING; CELL DIFFERENTIATION; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIGENS; CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; MELANOMA; NEOPLASM STAGING;

EID: 34548611603     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.354     Document Type: Review

References (42)

1. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50.
2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245.
4. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999;72:255.
5. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271.
6. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767.
7. Faries MB, Morton DL. Therapeutic vaccines for melanoma: Current status. BioDrugs 2005;19:247.
8. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1.
9. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556.
10. Penninger JM, Wen T, Timms E, et al. Spontaneous resistance to acute T-cell leukaemias in TCRV gamma 1.1J gamma 4C gamma 4 transgenic mice. Nature 1995;375:241.
11. Wang TS, Lowe L, Smith JW, et al. Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg 1998;24:915.
12. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998;9:757.
13. Bair FE. Melanoma. In: A Cancer Source Book for Nurses. Detroit, MI: Omnigraphics, 1990:277.
14. Kavanagh D, Hill AD, Djikstra B, et al. Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surgeon 2005;3:245.
15. Bystryn JC, Reynolds SR. Melanoma vaccines: What we know so far. Oncology (Williston Park) 2005;19:97.
16. Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669.
17. McIlroy D, Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: Maturation state does have clinical impact. Cancer Immunol Immunother 2003;52: 583.
18. + hematopoietic progenitor cells. Int J Cancer 2000;86:385.
19. + progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451.
20. Rodriguez A, Regnault A, Kleijmeer M, et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1:362.
21. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507.
22. Inaba K, Metlay JP, Crowley MT, et al. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T-cells in situ. J Exp Med 1990;172:631.
23. + cytotoxic T-lymphocytes by dendritic cells. J Exp Med 1987;166:182.
24. Saleh F, Renno W, Klepacek I, et al. Melanoma immunotherapy: Past, present, and future. Curr Pharm Des 2005;11:3461.
25. Grabbe S, Bruvers S, Gallo RL, et al. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656.
26. Ossevoort MA, Feltkamp MC, van Veen KJ, et al. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emph Tumor Immunol 1995;18:86.
27. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918.
28. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T-helper-cell-1-associated cytokines. J Exp Med 1996;183:87.
29. Nouri-Shirazi M, Banchereau J, Fay J, et al. Dendritic cell-based tumor vaccines. Immunol Lett 2000;74:5.
30. Ingram SB, O'Rourke MG. DC therapy for metastatic melanoma. Cytotherapy 2004;6:148.
31. Morton DL. Immunotherapy today: The story of a vaccine. J Drugs Dermatol 2005;4:672.
32. Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669.
33. Escobar A, Lopez M, Serrano A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005;142:555.
34. Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006;55:819.
35. Akiyama Y, Tanosaki R, Inoue N, et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 2005;3:4.
36. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328.
37. Panelli MC, Wunderlich J, Jeffries J, et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487.
38. + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165:3492.
39. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24:66.
40. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243.
41. Smithers M, O'Connell K, MacFadyen S, et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 2003;52:41.
42. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387.